CVRx Announces Positive News on Outpatient Payment for Barostim
This proposal follows two other positive developments in the last nine months relating to reimbursement rates. As of Oct. 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. In that same month it was announced that Barostim will transition from Category III to Category I CPT codes for physician payments as of Jan. 1, 2026. These reimbursement updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum.
'We appreciate CMS' proposal to keep Barostim in APC 1580, ensuring appropriate payment for the Barostim implant procedure,' said Kevin Hykes, President and CEO of CVRx. 'These reimbursement updates, along with the favorable proposed payment levels included in the recently released physician fee schedule, allow us to continue our progress toward expanding access to Barostim for patients suffering from heart failure with reduced ejection fraction, which we believe will help support its broader market adoption and long-term growth.'
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about the proposal to maintain the APC for the Barostim implant procedure and progress toward expanded access to Barostim are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ from our expectations, including the final OPPS rule, which could differ from the proposed rule, following the public comment period, and the actual impact of the APC on actual reimbursement and patient access. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@cvrx.com
Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@cvrx.comSign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Coinbase Global (COIN): 'For All I Know It's A Pump And Dump, I Don't See Anybody Dumping?' Says Jim Cramer
We recently published . ABC is one of the stocks Jim Cramer recently discussed. Coinbase Global, Inc. (NASDAQ:COIN) is a cryptocurrency exchange whose 57% year-to-date share price gain has resulted from legislation benefiting stablecoins and the bullish run in Bitcoin. Cramer's previous comments about Coinbase Global, Inc. (NASDAQ:COIN) asserted that the firm has benefited from its large market share. This time, he discussed Coinbase Global, Inc. (NASDAQ:COIN)'s valuation: '[On Cantor going to $500] I think that's within reason. PE's of these companies, this is the lowest one in park, at 40 times earnings, well Robinhood's not that low yet, I mean not that high. I mean People have to understand P/E analysis is not working. Robinhood's at 62 times earnings. COIN is at 40 times earnings. And people will say, uh, Jim, the multiple's too high. And I come back and say, do you really think the retail investor knows what a multiple is? Like what are you like, some sort of abstraction? See, this is a new world. I'm realistic. Look, for all I know it's a pump and dump, I don't see anybody dumping? I'll tell you when it's over. When the insiders do big deals and sell. And when there's secondaries. And there haven't been. That's what caused 2014. That's what caused it to end. 2020. That's what caused it to end. I mean, 2000. That's what caused it. 2000 being the vicious number of secondaries between January and March of 2021 and also about 2020. These years were just horrendous. And these companies broke down. I'm waiting for that. But it's not happening. So I wanna give people my history. Which is that it should have happened by now. Like Karp should have been selling and the companies should have been raising money. But they don't need to. These companies are incredibly well capitalized. And when people want to try and say, you know what they're like what happened to the dotcoms, I remember the dotcoms. They didn't have any money.' While we acknowledge the potential of COIN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
6 minutes ago
- Yahoo
Wendy's Pops on Meme Stock Hype. How Should You Play WEN Here?
Wendy's (WEN) shares shot up some 10% at market open on Wednesday, July 23 amid broader meme stock frenzy, with retail traders rotating into names with elevated short interest. The fast-food chain, with a tad above 11% of its float sold short, joined the ranks of Krispy Kreme (DNUT) and GoPro (GPRO) as speculative favorites. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Even at its intraday peak, however, Wendy's stock was down 25% versus its year-to-date high. Could Upcoming Earnings Lift Wendy's Stock? While a short squeeze often comes with its own set of risks, WEN shares remain unattractive also because the Nasdaq-listed firm has been struggling to improve its fundamentals. Wendy's is scheduled to report its second-quarter financial results on Aug. 8. Consensus is for it to earn $0.25 a share – down from $0.27 it earned on a per-share basis in the same quarter last year. Two Big Reasons to Own WEN Shares The aforementioned concerns also made BTIG analyst Peter Saleh reiterate his 'Neutral' rating on Wendy's shares ahead of its earnings scheduled for early August. According to Saleh, the fast-food company must commit to remodeling and modernizing its stores if it wishes to compete with the likes of McDonald's (MCD). That said, WEN stock is not entirely out of reasons to attract investors. For starters, it pays a super lucrative dividend yield of 5.1% at writing, particularly appealing for income investors. Additionally, shares of the globally popular restaurant chain are currently going for a forward price-earnings (P/E) multiple of 11.7x only – not even half the 24x on its larger peer, McDonald's. Wall Street Sees Significant Upside in Wendy's What's also worth mentioning is that other Wall Street analysts believe Wendy's stock will extend gains in the second half of 2025. Heading into its earnings release on Aug. 8, the consensus rating on WEN shares sits at 'Hold' only, but the mean target of $14.17 indicates potential upside of about 30% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Stock Market Today: S&P 500, Nasdaq Touch Records; Rail Merger Talks; West Pharma in Focus
Stock Market Today: S&P 500, Nasdaq Touch Records; Rail Merger Talks; West Pharma in Focus originally appeared on TheStreet. Morning Market: S&P and Nasdaq Touch Records The S&P 500 and Nasdaq Composite touched all-time highs, thanks to a strong showing from Alphabet. They're up 0.16% and 0.07% respectively at last check. West's Pharma's Very Green Day Keeping with the theme of health-care outperformance this week, West Pharmaceutical () is sitting atop the S&P 500 this morning. It's up 23%, thanks to its earnings report. The medical equipment maker raised its annual forecast, crediting GLP-1 demand. GLP-1 meds are used to treat diabetes and obesity. Competitors Labcorp () and Charles River () were the index's second and third-best performers, up 9.1% and 8.1% respectively. All Aboard the Strugglebus At the same time, auto-parts builder LKQ () is down 21%, touching a 52-week low, after missing analyst estimates of its earnings. It cut its full-year guidance, too, citing weak demand for auto services and parts. Guidance Up Short at American Air In April American Airlines CEO Robert Isom said that domestic travel declined "considerably" after President Trump took office. At the time, travel brands were pulling their guidance, citing economic uncertainty. And while some brands have paled back their concerns in recent weeks, American Air still faces some issues. It beat Wall Street estimates with $14.39 billion of Q2 revenue (vs. $14.3 billion expected) and earnings per share of 95 cents (vs. 78 cents expected), the airline issued guidance that was lighter than analysts were hoping for. The shares are down 7% in early trading. Rise and Shine: Morning Reports Earlier this a.m. we noted a few other big reports to keep an eye on. Those reports are now out, too. Here's how those companies are faring: Alternative-investments giant Blackstone () is up 2.9% after a healthy Q2 beat, with profit rising 25% year-over-year. Industrial and technology group Honeywell is down 4.3% after margins narrowed in its latest report. The Paris oil-and-gas player TotalEnergies is down 2.8% after lower oil and gas prices weighed on its business. Union Pacific Confirms Merger Talks with Norfolk Southern Going into its earnings report today, Union Pacific () was already the talk of Wall Street, due to murmurs that the railroad giant was considering a merger with competitor Norfolk Southern () . Well, aside from the strong revenue and earnings beat that America's largest railroad booked in its latest quarter, it confirmed the speculation as well. However, Union Pacific warns investors: There are no guarantees about whether such a deal could come about. If the two companies connect, they'll be far away the largest rail owner in the country, making a major change to an industry that already has concentrated down to a few companies. Meantime, at last check the Dow 30 are 0.6% lower and the S&P 500 is flat. Nasdaq Composite futures are 0.23% in the green. Treasury Yields Higher After Jobless Claims Data U.S. Treasury yields rose after jobless claims declined last week by 4,000 to 217,000. That was about 10,000 less than analysts expected. In addition, as was widely expected, the European Central Bank chose to leave its deposit facility rate at 2%. This comes after the bank made the decision to cut in recent meetings. 💸💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰💸 Taken together, investors have pushed up the yield on the 10-year by about 4.5 basis points (+1.03%) this morning. It's now sitting at 4.427%. Stocks are little moved in the premarket, with the S&P about 0.11% higher. Per Nasdaq, we're looking for 186 reports today; today's four most-valuable reports all are due out in short order. Industrial heavyweight Honeywell () , energy company TotalEnergies () , railroad giant Union Pacific () and investment firm Blackstone () will report results this morning. Later this afternoon, we'll be looking for results from beleaguered chipmaker Intel () , gold mining firm Newmont () , and data center REIT Digital Realty Trust () , among others. Megacaps Trading Places When Tesla () and Google parent Alphabet () reported yesterday, it was the automaker that registered a small gain despite its worst revenue decline in years — not the advertising-and-search-and-cloud business, which handed investors a healthy double beat against analyst estimates. This morning, they've flip-flopped. The key here is where that green box has trended (to orange). Alphabet is up nearly 4% in premarket trading, putting it at about $197.56 at last glance. And Tesla is now sitting more than 5% below where it ended trading yesterday, at about $313.65 at the moment. Could be worse, though. International Business Machines () has been getting hammered despite strong earnings. A miss on software revenue was to blame. It's down 6.1% this morning. Tariff Talks, Gold Jitters Notably, gold was even lower this morning after yesterday's tariff rumors. The safe haven metal gyrated yesterday on reports that the U.S. was close to a trade deal with the European Union. At last check it was down $28.90 (-0.85%) to $3,368.60. Here's how it's looking so far this year: Stock Market Today: S&P 500, Nasdaq Touch Records; Rail Merger Talks; West Pharma in Focus first appeared on TheStreet on Jul 24, 2025 This story was originally reported by TheStreet on Jul 24, 2025, where it first appeared. Sign in to access your portfolio